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Abstract:  The  inherited  disorders  of  hemoglobin  are  by  far  the  commonest  monogenic 
diseases and there is considerable evidence that they have reached their very high frequencies 
due to heterozygote advantage against malaria.  Recent studies have begun 
of interactions between malaria and some of the more severe inherited hemoglobin disorders 
and demonstrated how complex epistatic interactions between different hemoglobin variants 
with respect to malaria resistance and modification o
the  remarkable  heterogeneity  of  distribution  and  the  frequency  of  these  conditions  both 
between and within individual populations.
Introduction:  It  was  estimated  recently  that 
over seven million babies are born each year with 
either a congenital abnormality or genetic disease, 
and that up to 90% of these births occur in low or 
middle-income  countries.
1    Of  these  conditions, 
approximately 25% are made up of five disorders, 
two of which, the inherited disorders of hemoglobin 
and glucose-6-phosphate dehydrogenase deficiency, 
are  monogenic  diseases.  It  is  estimated  that  in 
excess of three hundred thousand children are born 
each year with either sickle cell anemia or one of its 
variants or one or other form of thalassemia.
There  is  now  extensive  eviden
extremely  high  frequency  of  the  hemoglobin 
disorders compared with other monogenic diseases 
reflects  natural  selection  mediated  by  the  relative 
persistence  of  carriers  against  P.  falciparum
malaria.  Other factors that maybe involved include 
the  widespread  practice  of  consanguineous 
; Open Journal System 
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
www.mjhid.org ISSN 2035-3006
into  the  Population  Genetics and  Dynamics  of  t
Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, UK
Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, OX3 
9DS, UK. Tel: +44 1865 222 360, Fax: +44 1865 222 424. E-mail: liz.rose@imm.ox.ac.uk
e200922 DOI 10.4084/MJHID.2009.022
http://www.mjhid.org/article/view/5228
This  is  an  Open  Access  article  distributed  under  the  terms  of  the  Creative Commons  Attribution  License
http://creativecommons.org/licenses/by/2.0), which  permits  unrestricted  use,  distribution,  and  reproduction  in  any 
the original work is properly cited
The  inherited  disorders  of  hemoglobin  are  by  far  the  commonest  monogenic 
diseases and there is considerable evidence that they have reached their very high frequencies 
due to heterozygote advantage against malaria.  Recent studies have begun to clarify the effect 
of interactions between malaria and some of the more severe inherited hemoglobin disorders 
and demonstrated how complex epistatic interactions between different hemoglobin variants 
with respect to malaria resistance and modification of their phenotypic severity may explain 
the  remarkable  heterogeneity  of  distribution  and  the  frequency  of  these  conditions  both 
between and within individual populations.
It  was  estimated  recently  that 
over seven million babies are born each year with 
either a congenital abnormality or genetic disease, 
and that up to 90% of these births occur in low or 
Of  these  conditions, 
approximately 25% are made up of five disorders, 
two of which, the inherited disorders of hemoglobin 
dehydrogenase deficiency, 
are  monogenic  diseases.  It  is  estimated  that  in 
excess of three hundred thousand children are born 
each year with either sickle cell anemia or one of its 
variants or one or other form of thalassemia.
There  is  now  extensive  evidence  that  the 
extremely  high  frequency  of  the  hemoglobin 
disorders compared with other monogenic diseases 
reflects  natural  selection  mediated by  the  relative 
P.  falciparum
malaria.  Other factors that maybe involved include 
e  widespread  practice  of  consanguineous 
marriage,  increased  maternal  age  in  the  poorer 
countries, and gene drift and founder effects.
Over recent years there has been a major revival 
in interest in the study of interactions between the 
inherited  hemoglobin disorders and 
malaria, work that has been the subject of several 
extensive reviews.
2,3  Here, we shall focus on recent 
developments in this field, particularly with respect 
to  interactions  between  malaria  and  more  severe 
forms of the hemoglobin disorders and how a study 
of this interplay is starting to provide some insights 
into the remarkable variability of the distribution of 
these  diseases  among  different  populations.    We 
shall  also  address  briefly  some  of  the  potential 
practical implications of this new information.
The  current  state  of  malaria  transmission
Despite progress towards its control malaria is still 
the most important parasitic disease.  It is estimated 
that some three billion people reside in malarious 
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
the  Inherited 
dington, Oxford, OX3 
Commons  Attribution  License
which  permits  unrestricted  use,  distribution,  and  reproduction  in  any 
The  inherited  disorders  of  hemoglobin  are  by  far  the  commonest  monogenic 
diseases and there is considerable evidence that they have reached their very high frequencies 
to clarify the effect 
of interactions between malaria and some of the more severe inherited hemoglobin disorders 
and demonstrated how complex epistatic interactions between different hemoglobin variants 
f their phenotypic severity may explain 
the  remarkable  heterogeneity  of  distribution  and  the  frequency  of  these  conditions  both 
marriage,  increased  maternal  age  in  the  poorer 
countries, and gene drift and founder effects.
Over recent years there has been a major revival 
in interest in the study of interactions between the 
disorders and  P.  falciparum
malaria, work that has been the subject of several 
Here, we shall focus on recent 
developments in this field, particularly with respect 
to  interactions  between  malaria  and  more  severe 
obin disorders and how a study 
of this interplay is starting to provide some insights 
into the remarkable variability of the distribution of 
these  diseases  among  different  populations.    We 
shall  also  address  briefly  some  of  the  potential 
ions of this new information.
The  current  state  of  malaria  transmission: 
Despite progress towards its control malaria is still 
the most important parasitic disease.  It is estimated 
that some three billion people reside in malarious Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
areas and that the disease is responsible for between 
one  and  three  million  deaths  each  year.    Until 
recently  it  was  thought  that  only  four  species  of 
malarial  parasite  (Plasmodium)  have  humans  as 
their  natural  hosts;  P.  falciparum,  P.  vivax,  P. 
malariae, and P. ovale.  More recently it has been 
found  that  many  cases  of  malaria  that  were 
previously diagnosed as being due to P. malariae 
infection  are  in  fact  due  to  a  fifth  parasite,  P. 
knowlesi, particularly in Malaysia and Borneo.
4
Until  recently,  it  was  thought  that  the  P. 
falciparum malaria is by far the most severe form of 
the  condition  and,  globally,  the  major  cause  of 
mortality.    However,  over  recent  years  there  has 
been  increasing  evidence  that  malaria  due  to  P. 
vivax, which occurs at extremely high frequencies 
in parts of Asia and South America, may be a much 
more  serious  condition  than  was  previously 
realised.
5,6    Recent  evidence  suggests  that  it  may 
cause many of the serious complications of malaria 
that  have  usually  been  associated  only  with  P. 
falciparum, involvement of the brain for example.  
Thus in considering the interactions of malaria with 
the  haemoglobin  disorders  it  is  important  now  to 
focus not only on P. falciparum but also on P. vivax
malaria. 
Malaria and structural hemoglobin variants: 
There  is  now  extensive  evidence  suggesting  that 
relative resistance on the part of heterozygotes to P. 
falciparum malaria  has  been  the  major  factor 
underlying the extremely high gene frequencies of 
hemoglobins S, C and E.
Hemoglobin S.   Early comparative  studies  of 
parasite rates and density in children with the sickle 
cell trait and controls, together with the discovery of 
the relative rarity of Hb S in patients with severe 
malaria  in  Africa,  provided  convincing  evidence 
that  the  sickle  cell  trait  provides  at  least  some 
degree  of  protection  against  severe  malarial 
infection.
7    More  recent  studies  in  East  Africa 
suggest that the major impact of Hb S seems to be 
on protection against either death or severe disease, 
that is profound anemia or cerebral malaria, while 
having less effect on infection rates per se.
8  Indeed, 
these  studies  indicate  that  Hb  S  carriers  have 
approximately 60-80% protection against the severe 
complications  of  malaria.    Several  cellular 
mechanisms  that  might  underlie  this  protective 
effect have been clearly defined
3 although there are 
also data which suggest that an immune mechanism 
may also be involved.
9  
For many years it was believed that at least part 
of  the  extremely  high  mortality  of  babies  with 
sickle cell anemia in Africa might reflect death due 
to malarial infection.  However, in a recent study 
carried out on the coast of Kenya no evidence was 
found to support the concept that the risk of malaria 
is  higher  among  children  with  sickle  cell  disease 
than  among  normal  children.
10    In  fact,  a  related 
study from the same region has demonstrated that 
the pattern of infection in the early years of life of 
children with sickle cell disease is very similar to 
that in Western countries.
11  If confirmed in other 
regions, these findings have important implications 
regarding  antibiotic  and  malaria  prophylaxis  for 
patients  with this  disease  in  malaria-endemic 
regions.
Hemoglobin  C    Work  in  West  Africa  has 
demonstrated quite unequivocally that the relatively 
high frequencies of Hb C have also been maintained 
by resistance to P. falciparum malaria 
12.  In this 
case  it  appears  that  both  heterozygotes  and 
homozygotes  are  protected,  suggesting  that  Hb  C 
could be an example of a transient polymorphism, 
that is a variant that might be moving to fixation in 
a  population  in  which  the  selective  process 
continues.  This concept is based on the apparent 
lack  of  clinical  disability  in  Hb  C  homozygotes.  
However, further work is required to assess whether 
homozygotes  for  Hb  C  are,  in  genetic  terms, 
completely fit, that is whether the homozygous state 
is associated with absolutely no clinical disability.
Recent  studies  suggest  that  the  expression  of 
the  malarial  antigen  PfEMP1,  an  important 
adhesion molecule, is reduced in Hb C-containing 
red  cells,  an  effect  that  is  most  marked  in 
homozygotes.
13  The functional importance of this 
finding  compared  with  the  unusual  rheological 
properties of Hb C-containing red cells remain to be 
determined.
Hemoglobin E  Hb E, which produces a mild 
thalassaemia phenotype in homozygotes, occurs at 
an extremely high frequency in parts of the Indian 
subcontinent,  Bangladesh,  Myanmar,  and 
throughout Southeast Asia, reaching carrier rates of 
up  to  70%  in  parts  of  northern  Thailand  and 
Cambodia.  So far there have been no formal case 
control  studies  to  analyse  the interaction  between 
Hb E and malaria but population studies in Thailand 
have suggested that those with the Hb E trait show 
less severe disease when admitted to hospital with 
acute  P.  falciparum malaria.
14 Furthermore, 
convincing in vitro culture studies have shown that 
the  red  cells  from  Hb  E  heterozygotes,  but  not 
homozygotes, are more resistant to invasion by P. 
falciparum.
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Thalassemia  and  P.  falciparum malaria: 
Although the malaria hypothesis, as first proposed 
by Haldane, was first developed to explain the high 
frequency  of  the  thalassemias  it  has  taken  many 
years to confirm that Haldane was correct.  There is 
now  extensive  evidence  to  suggest  that  the  mild 
forms  of   thalassemia  reach  their  extraordinary 
high  frequencies  due  to  protection  against  P.
falciparum and  at least some  suggestive  evidence 
that the same applies to the  thalassemias.

+ thalassemia:   The 
+ thalassemias, which 
are most commonly due to deletions of one of the 
linked  globin genes, -/, are the commonest 
monogenic diseases in the world population.  They 
occur  in  a  broad  band  stretching  through  sub-
Saharan Africa and the Mediterranean, through the 
Middle  East  and  the  Indian  subcontinent  to 
Southeast  Asia.    The  frequency  in  these  regions 
varies fro 5-40% although in parts of Northern India 
and  Papua  New  Guinea  close  on  80%  of  the 
population are carriers.
16
Extensive population studies in the Southwest
Pacific  showed  a  strong  correlation  between  the 
distribution  of  
+ thalassemia  and  malaria,  and 
related  molecular  analyses  indicated  that  the 
particular  form  of  
+ thalassemia  in  these 
populations  is  different  to  that  and  the  Asian 
mainland.
17  An unusual feature of the distribution 
of  
+ thalassemia  in  this  region  is  that  it  is  also 
found in Fiji in the west and Tahiti in the east and in 
other populations in which malaria has never been 
recorded.  However  in  these  regions  all  the  
+
thalassemias  can  be  accounted  for  by  a  single 
mutation  which  was  first  identified  in  Vanuatu, 
suggesting that their occurrence in these areas has 
been the result of population migration and founder 
effect.
18
These  findings  were  later  augmented  by  case 
control studies in Papua New Guinea where it was 
found that, compared with normal children, the risk 
of  being  admitted to hospital  with severe  malaria 
was significantly reduced, both for 
+ thalassemia 
homozygotes  and  heterozygotes.
19    More  recently 
these  findings  have  been  replicated  in  several 
African populations and it is now absolutely clear 
that the 
+ thalassemias do offer protection against 
P.  falciparum.
20,21    Both  cellular  and  immune 
mechanisms have been found that may offer at least 
a partial explanation to the protective effect of 
+
thalassemia  against  malaria.    The  red  cells  of 
individuals with 
+ thalassemia bind more malaria-
immune  globulin  than  normal  and  appear  to  be 
more  susceptible  to  phagocytosis  in  vitro.
22    In 
particular, they are less able than normal to form 
rosettes, an in vitro phenomena whereby uninfected 
red cells bind to infected cells.  This may affect a 
reduced  expression  of  complement  receptor  1 
(CR1)  expression  on   thalassemic  red  cells.
23
These cells are also less able to adhere to human 
umbilical vein endothelial cells.
24  Taken together it 
does appear that  thalassemic red cells may be less 
able  to  sequester  in  blood  vessels,  an  important 
mechanism for virulence of infection.  It has also 
been suggested recently that the relatively high red 
cell counts in this condition may offer some degree 
of  protection  against  the  profound  anemia  of 
malaria  in  early  life.
25 We  will  consider  other 
possible  immune  mechanisms  mediated  by  
+
thalassemia in a later section.
 thalassemia:  With the exception of a small-
scale case control study in Liberia, which suggested 
that  the   thalassemia  trait  is  protective  against 
severe  malaria,  there  have  been  no  large-scale 
studies  of  this  type.
26    There  is  however  a 
considerable body of epidemiological data relating 
the  frequency  of   thalassemia  to  malaria 
transmission  that  indicates  that  it  too  may  be  a 
protective  polymorphism  against  malaria,  a 
conclusion  that  is  strengthened  by  the  pattern  of 
haplotype  analysis  of  the   globin  genes  in 
relationship to different  thalassemia mutations.
16  
Furthermore, work in both human blood cells
27 and 
in  the  cells  of  transgenic  mice  carrying  human  
globin  genes,
28 it  has  been  found that  red  cells 
which  contain  human  fetal  hemoglobin  are 
associated  with  ineffective  development  of  P. 
falciparum or  P.  yoelli.    Since  there  is  clear 
evidence that the rate of decline of fetal hemoglobin 
production  after birth is delayed  in  thalassemia
heterozygotes
16 this  could  offer  a  further 
mechanism  of  protection  during  the  first  year  of 
life.  
Plasmodium  vivax infection  and  the 
hemoglobinopathies: Early studies in Africa,
29 and 
later in Papua New Guinea,
30 revealed a very high 
frequency  of  the  Duffy-negative  blood  group 
phenotype  in  populations  in  which  malaria  is 
common.  Red cells lacking the Duffy determinant 
are  resistant  to  invasion  by  both  P.  vivax and  P. 
knowlesi,  explaining  the  almost  complete  absence 
of P. vivax malaria in many parts of Africa.
31  This 
red  cell  phenotype  results  from  a  mutation  in  a 
GATA-1  binding  site  in  the  gene  for  the  Duffy 
antigen  chemokine  receptor  (DARC)  which 
prevents  its  expression  and  hence  the  Duffy 
negative phenotype.
32
Given  this  remarkable  example  of  a  malaria 
protective polymorphism it is surprising that there Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
have been, to date, very few studies of the possible 
interaction  between  the  hemoglobin  disorders and 
P. vivax malaria.    In  a  cohort  study of  babies  in 
Vanuatu it was found, surprisingly, that those with 
 thalassemia  had  a higher  frequency  of  malaria 
during  the  very  early  years  of  life  than  normal 
infants and that this was most marked in the case of 
P. vivax malaria.
33  This led to the suggestion that
one  of  the  possible  mechanisms  of  resistance  to 
falciparum malaria in children with  thalassemia 
might  reflect  early  immunization  with  P.  vivax
malaria, the later protection against  P. falciparum
reflecting  cross-immunization  between  the  two 
varieties  of malarial  parasite.
33    A  later  study  in 
Papua  New  Guinea  also  observed  a  highly 
significant increase in parasitemias in babies with 
thalassemia compared with normal infants.
19  There 
is a possible mechanism for this observation.   The 
Duffy  antigen  is  expressed  at  a  greater  level  in 
young  red  cell  precursors  and  hence  in  any 
condition  where  there  is  a  rapid  turnover  of  red 
cells, and hence a younger red cell population in the 
peripheral blood, an  increased  susceptibility  to  P. 
vivax might occur.  
Very recently a study has been reported from 
Sri  Lanka  in  which  the  susceptibility  of  children 
with  HbE   thalassemia  to  both  P.  vivax and  P. 
falciparum malaria was assessed.
34  Compared with 
control subjects, it appeared that those with HbE 
thalassemia were more susceptible to both forms of 
malaria, but particularly to P. vivax.  Interestingly, 
those who had been splenectomized appeared to be 
particularly  susceptible,  but  even  the  malarial-
antibody levels in children with intact spleens were 
significantly  higher  than  those  in  age-matched 
controls.  Evidence of previous vivax infection was 
also related to spleen size and hence to the severity 
of the thalassemic phenotype.  Again, it is possible 
that the increased susceptibility to P. vivax reflects 
the  rapidly-turning-over  red  cell  population  of 
children with HbE  thalassemia.
Clearly  therefore  it  will  now  be  important to 
study the  effects of  the heterozygous  states for 
thalassemia  and  hemoglobin  E  with  respect  to 
susceptibility to P. vivax.  From a clinical point of 
view,  since  P.  vivax malaria  is  presenting  an 
increasingly  serious  health  problem  in  Asian 
populations where HbE  thalassemia is so common 
it will also be important to repeat these studies in 
other parts of Asia to determine whether P. vivax
prophylaxis  should  become  an  integral  part  of 
thalassemia  control  programs  in  countries  where 
this form of malaria is particularly common.
The  significance  of  interactions  between 
different malaria-resistant polymorphisms
Since different hemoglobin variants or forms of 
thalassemia  that  offer  protection  against  malaria 
frequently occur together in the same population it
is  important  to  determine  how  they  interact  with 
one  another  with  respect  to  the  level  of  malaria 
protection.  The term epistasis is used to describe 
potential  interaction  between two or  more loci of 
this kind.  Interestingly, the first study of this kind, 
in  east  Africa,  has  shown  that  there  is  negative 
epistasis between the sickle cell and  thalassemia 
genes  with  respect  to  protection  against  P. 
falciparum.
35  As discussed above, while the sickle 
cell trait or the heterozygous or homozygous state 
for   thalassemia  alone  provide  significant 
protection, this effect is almost completely nullified 
in  those  who  are  heterozygous  for  Hb  S  and 
homozygous  or  heterozygous  for  
+ thalassemia.  
This  may  reflect  the  intracellular  level  of  Hb  S.  
Those who inherit the  thalassemia gene together 
with  the  sickle  cell  trait  have  significantly  lower 
levels of Hb S compared with those who have the 
sickle cell trait alone.
Recently,  there  has  been  a  particularly 
interesting  twist to  the  story  of  these  interactions 
with respect to the distribution of the sickle cell and 
thalassemia genes in Africa and the Mediterranean 
populations.  Although the sickle cell gene occurs to 
a  modest  degree  in  some  though  not  all 
Mediterranean  populations  the  predominant 
hemoglobin variants in these regions are the  and 
 thalassemias.  On the other hand,  thalassemia, 
with  the  exception  of  some  localized  parts  of 
Liberia,  is  relatively  rare  across  the  African  sub-
continent, where the sickle-cell and  thalassemia 
mutations predominate.  It has been shown recently 
that  this state of  affairs  can  be explained by  two 
epistatic  interactions,  one  that  we  have  just 
described in the case of the sickle cell trait and 
thalassemia, together with the ameliorating effect of 
 thalassemia on the phenotype of the severe forms 
of   thalassemia.
36    By  modelling  these  two 
interactions within populations it has been possible 
to explain much of the present discrepancies in the 
regional distribution  of  these hemoglobin variants 
in Africa and the Mediterranean region.  Since the 
disparate  distribution  of  different  hemoglobin 
variants in different parts of the world has always 
remained a puzzle, it will be interesting to apply a 
similar  approach  to  their  distribution  in  other 
populations.Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
Conclusion: In this short review I have tried to 
highlight  some  recent  information  obtained  from 
the  studies  of  the  relationship  between  the 
hemoglobin  disorders and  malaria,  set  against  the 
background of the considerable amount of progress 
that has been made in this field over recent years.  
Several  aspects  of  this  work  have  interesting and 
potentially  important  implications  for  the 
hemoglobin field.
Currently,  we  have  only  an  extremely 
approximate  estimate  of  the  global  burden  of 
disease that is being produced by the hemoglobin 
disorders.  This is largely due to lack of accurate 
information  about  gene  frequencies  in  individual 
populations 
16.    Recent  micro-mapping  studies 
suggest that, even within relatively small population 
groups,  Sri  Lanka  for  example,  there  is  a 
remarkable heterogeneity in the distribution of the 
hemoglobin  variants.
37    While  it  always  seemed 
possible that this reflected similar heterogeneity in 
the distribution of malaria, and indeed this appears 
to be the case in Sri Lanka, it is now apparent that it 
may also result from complex epistatic interactions, 
not  just  between  the  variants  themselves  but  also 
with  respect  to  the  resulting  effect  on  malaria 
resistance.    The  epistatic  interaction  between  the 
sickle  cell  and   thalassemia  traits  in  Africa  are 
quite remarkable.  If malarial vaccines are going to 
be tested in populations with a high frequency of 
these  traits,  particularly  if  they  are  attenuating 
vaccines,  it  will  be  extremely  important  to 
understand  the genetic  background  of  the 
populations  being  tested  with  respect  to  the 
frequency  and  potential  interactions  of  these 
variants.  And of course these interactions are also 
of major biological and evolutionary interest with 
respect  to  the  distribution  of  the hemoglobin 
variants in the current global population.
The early data that has come from studies of the 
interaction of malaria with the more severe forms of 
thalassemia, notably sickle cell anemia and Hb E 
thalassemia,  are  also  of  potential  importance.    It 
will be extremely important, for example, to repeat 
the  susceptibility  studies  to  P.  vivax malaria  of 
patients with Hb E  thalassemia in those parts of 
Asia where P. vivax malaria is presenting a major 
health problem and where Hb E  thalassemia is 
particularly common.  Similarly, the observations of 
the apparent lack of susceptibility of patients with 
sickle cell disease to P. falciparum malaria provides 
important  information  about  future  design  of 
programs for the better control and management of 
sickle cell anemia in African populations.
Finally, although some progress has been made 
the precise mechanisms of malaria protection by the 
hemoglobin  variants  and  different  forms  of 
thalassemia is still uncertain.  This is an important 
question  because  it  is possible  that  if  these 
mechanisms  were  better  understood  they  might 
offer  valuable  clues  to  the  development  of 
completely different approaches to the control and 
management  of  malaria.   It is interesting that  the 
discovery that DARC is the receptor for P. vivax on 
red cells, which led to the discovery of the parasite 
antigen which interacts with this receptor, has led to 
the development of at least one promising target for 
vaccine  production.
38    It  is  very  important  to 
determine  whether  there  are  other  lessons  of  this 
kind  that  remain  to  be  learned  from  a  better 
appreciation  of  the  mechanisms  of  protection 
against malaria by other hemoglobin or related red 
cell polymorphisms.
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